Hereditary inclusion body myopathy gene therapy (Gradalis)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHereditary inclusion body myopathy gene therapy (Gradalis)
Drug Alias NameGNE Lipoplex
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionGNE gene transference
TargetsBifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase
Therapy Area/IndicationsDistal Myopathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGradalis Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGradalis Inc
Active IndicationsN/A
Inactive IndicationsDistal Myopathies

Other Information

ATC CodeN/A
Related LinksN/A